Participants

Ahmed Adel Seida
Participant
[Egypt] I obtained my bachelor degree in Veterinary Sciences in 2003, Faculty of Veterinary Medicine, Cairo University and followed by Master degree in Immunology in 2006 from same faculty. November 2012, I got my PhD degree in Immunology from Würzburg University, Germany. In November 2013 till present, I am University Lecturer of Immunology, Vaccinology and Microbiology at Faculty of Veterinary Medicine, Cairo University, Egypt.
Alphonse Ouedraogo
Participant
[Burkina Faso] Dr. Ouédraogo has a Doctor of Medicine degree in 2002 from the School of Medicine at the University of Ouagadougou (Burkina Faso). In 2013, he obtained a Ph.D. in medical epidemiology from the University of Roma Sapienza (Italy). During his career, he has progressively gained more expertise in malaria epidemiology and clinical trials. He currently serves as the Head Scientist of the Development of New Drugs and Vaccines Laboratory for CNRFP.
Amed Ouattara
Participant
[United States] I am a Research Associate at the Center for Vaccine Development and Global Health, University of Maryland, Baltimore. I use a diversity-covering approach that incorporates polymorphisms from various malaria parasite alleles into the design of a multivalent vaccine to address the issue of antigen diversity.The approach prioritize malaria vaccine antigens and, importantly, variants of these antigens based on a systematic evaluation of their worldwide genetic diversity and haplotype prevalences.
Angela Choi
Participant
[United States] Angela is a PhD candidate at Icahn School of Medicine at Mount Sinai in Dr. Adolfo García -Sastre’s laboratory. Her research focuses on how pre-existing immunity to influenza modulates virus-host interactions in the antigen-experienced host. Specifically, she is trying to dissect the different aspects of both the innate and adaptive branch of the host immune response to vaccination and repeated influenza virus infections, and how these parameters contribute to long-lasting protection.
Aroon Chande
Participant
[United States] Aroon Chande is a Ph.D. student in the Jordan Lab at Georgia Institute of Technology and a Bioinformatics Scientist with the Applied Bioinformatics Laboratory. His Ph.D. focuses on recently admixed populations in Colombia and ancestry-specific health disparities. His work at the Applied Bioinformatics Laboratory supports public health initiatives across the United States through software development, workforce development training, and bioinformatics research.
Beatriz Meza
Participant
[México] Beatriz Meza-Márquez. I am a doctoral student in the Center for Biological Research of the Northwest (CIBNOR, México). My current research is in the final stages of the development of a multiantigenic, multistage and multi-epitope vaccine against Helicobacter pylori.
Camille L. Novis
Participant
[Unites States] Dr. Novis obtained a Bachelor’s degree from the Universidade Federal Fluminense, Brazil. During her undergraduate studies she was a CNPq fellow at FIOCRUZ. In 2015, she obtained her Ph.D. in Immunology & Microbiology from the University of Utah, USA. As a Ph.D. candidate, she described HIV latency-reversal compounds. Currently, as a postdoctoral fellow, Dr. Novis studies the effect of epigenetics in Tfh cell differentiation and its contribution to the improvement of humoral immunity.
Carolina M. Andrade
Participant
[Germany] Young scientist with a strong knowledge of host-pathogen interactions, mainly in Plasmodium parasites. Currently developing her PhD studies investigating host and parasite factors that influence the dry season maintenance of P. falciparum in Mali.
Caroline Cleopatra Chisenga
Participant
[Zambia] Dr. Caroline is a Postdoctoral Research Fellow at the Centre for Infectious Diseases Research in Zambia (CIDRZ) and works under the Enteric Disease and Vaccine Research Unit. She obtained her PhD degree in immunology from the University of Zambia. Her current role involves profiling vaccine immune responses in infants in a clinical trial scenarios.
César López-Camacho
Participant
[United Kingdom] Dr. César holds a PhD in Molecular Biology by the U. of Manchester,UK and he did two postdoctoral fellowships in the USA at the U. of Massachusetts Med. School and U. of Vermont. He is now a senior postdoctoral scientist in Reyes-Sandoval’s Lab at The Jenner Institute, U. of Oxford. His research focuses in the development of vaccines against ZIKV, DENV, CHIKV and MAYV using replication-deficient simian adenovirus and MVAs. He collaborates in vaccine designs/cloning for Chagas, Malaria, and HPV.
Daniela Pencheva
Participant
[Bulgaria] I am microbiologist with practice in the field of quality control of in vitro diagnostic medical devices, but am also a scientist with an interest in experimental work in the area of vaccinology. My scientific activity is with the contribution of the National Center of Infectious and Parasitic Diseases: Sofia, Bulgaria. Furthermore, I work also as a lecturer in the University Of Chemical Technology And Metallurgy, Sofia, Bulgaria.
Danilo Legisa
Participant
[Argentina] Danilo Legisa, PhD. I am R&D and fermentation analyst at Center for R&D in Industrial Biotechnology at INTI-Argentina: a state institution aimed to develop and transfer bioprocess technology to regional industries and academia. As PhD student I`ve been working on Bluetongue Virus (vaccine development and epidemiology) and as post doc on diagnosis kit development for hemolytic uremic syndrome. Currently University Instructor at UNLaM and also Biotech entrepreneur.
Dismas Oketch
Participant
[Kenya] Dr. Dismas Oketch (MD) is the Associate Director of the Kenya Medical Research Institute’s HIV Prevention Clinical Trials & Linkage to Care. He holds an MBChB from Moi University, an MSc in Clinical Trials from the University of London, and spires to be a global leader in the field of vaccines and immunotherapy within the decade. He currently leads the AMP and LIFE studies - two large and pivotal NIH-funded HIV prevention clinical trials at the KEMRI-CDC Clinical Research Center.
Erick Muok
Participant
[Kenya] Dr. Muok has a Ph.D. in Immunology in 2014 from the Jomo Kenyatta University of Technology in Nairobi. From 2015 to 2018 he was a postdoctoral fellow at Emory University, USA and the Rwandan-Zambian HIV research group. Since 2014 he is a Senior research officer at the Center for global Health Research of KEMRI in Kisumu , Kenya. His laboratory studies is in the early Immune responses in acute HIV infection and HIV co-morbidity with Schistosomiasis.
Erwan Atcheson
Participant
[United Kingdom] Dr Erwan Atcheson is a post-doctoral scientist working on vaccines for Hepatitis C virus, using a novel rat/rodent hepacivirus model, at the Medawar Building for Pathogen Research. He completed a DPhil (2017) developing novel vaccines for malaria (P. vivax and P. falciparum), including mathematical modelling of vaccine combinations, screening of new epitopes using highly immunogenic virus-like particles, and viral-vectored vaccines.
Fabiana Leoratti
Participant
[Switzerland] Dr. Fabiana Leoratti graduated in Pharmacy Biochemistry in 1998. In 2004 she obtained a Master’s degree and in 2008 a PhD in Sciences from the University of São Paulo. Since 2016, she is Research fellow at University of Bern/Inselspital Department Rheumatology, Imunology and Allergy, where her research involves the development of vaccines in HIV using VLP (Virus like particles).
Federica Ghersa
Participant
[Argentina] Masters in Immunology student and finishing my PhD in Biochemistry focused on endometriosis. Currently applying for a postdoc position initiating formation in nanotechnology in vaccine development in INTA-Bariloche and INIBIOMA-CONICET.
Gerardo Montalvo Zurbía Flores
Participant
[United Kingdom] Gerardo has been awarded a BSc in Biology and a MSc in Medical Virology. Currently, he is undertaking a DPhil in Clinical Medicine which aims to design novel strategies towards the development of a multi-disease vaccine against medically important arboviruses such as Dengue, Zika, Yellow Fever, Chikungunya and Mayaro virus.
Gianmarco Gasperini
Participant
[Italy] Gianmarco Gasperini is a scientist working in the molecular biology unit of GSK Vaccines Institute for Global Health, a company dedicated to the development of affordable vaccines for impoverished countries. He obtained his PhD in Cellular and Molecular biology as part of a joined program between the University of Bologna (Italy) and Novartis Vaccines and specialized in the field of antigen identification for vaccines against bacterial pathogens.
Hugo Alberto Valdez
Participant
[Argentina] Dr. Valdez graduated in Molecular Biology in 2005. In 2010, he obtained a Ph.D. in Molecular Biology and Biotechnology from the National University of San Martin. Since 2014, he is Professor at the University of San Martin. He is also a Assisten Researcher at the Argentinean Research Council, where he carries out research focuses on whooping cough problems, the persistence mechanisms used by the bacterium and development a new vaccine against Bordetella pertussis and Bordetella parapertussi.
João Paulo Portela Catani
Participant
[Belgium] Dr. João Paulo Portela Catani obtained an engineer degree at the Federal University of Paraná and a master degree at the University of Cergy-Pointoise. In 2014, he obtained a PhD in Sciences at the University of São Paulo. He is currently a post doc at the University of Ghent and his current research is focused in mRNA delivery for immuno-modulatory purposes.
Kwadwo Asamoah Kusi
Participant
[Ghana] Dr. kwadwo Asamoah Kusi is a Senior Research Fellow in the Immunology Department of Noguchi Memorial Institute for Medical Research, University of Ghana. He has training in biochemistry and parasite immunology and graduated with a PhD in Medicine from the Leiden University Medical Centre in the Netherlands. His current research is on the development of vaccine formulation strategies that aim to overcome the strain-specific effects of malaria parasite antigen polymorphisms on vaccine responses.
Linda E Amoah
Participant
[Ghana] Dr Linda E Amoah obtained a PhD from Georgetown University, Washington DC in 2007. She worked at MR4, VA, USA for two years then joined the NMIMR, University of Ghana in 2009. Her laboratory uses the L. lactis system to express essential malaria antigens and is generally interested in the identification and design of new transmission blocking vaccines and drugs as well as identifying parasite and host genetic traits that influence the infectiousness of Plasmodium gametocytes.
Lorena Preciado-Llanes
Participant
[United Kingdom] Lorena is a postdoctoral researcher at the University of Oxford, working on vaccine trials against arboviruses. After obtaining her medical degree in Mexico, she undertook an MSc and PhD in infection and immunity at the University of Sheffield (UK). Her research interests include human challenge models, host-pathogen interactions and adaptive immune responses to vaccines.
Manisha Pandey
Participant
[Australia] Dr Manisha Pandey is a Senior Research Fellow and Team Leader-Streptococcal Research at the Institute for Glycomics, Griffith University, Australia. She is a translational vaccinologist working on vaccine development for group A streptococcal infections. Her research interest focuses on investigating mechanistic aspect of vaccine mediated immunity in the context of host –pathogen interaction, understanding of which is critical to designing and further improvement of the vaccine.
María José Germanó
Participant
[Argentina] Maria José has a degree in Molecular Biology at National University of San Luis. From 2013 at 2016 she was auxiliary professor of chemistry at National University of San Luis. She is PhD student at National University of Cuyo. Currently, she is working on first and thirst generation vaccines against leishmaniasis.
Mariateresa Coppola
Participant
[Netherlands] Mariateresa Coppola works as a PhD student in the group of Tom Ottenhoff where she moved to after obtaining her medical degree from Sapienza University in 2013. She uses genomics, in-silico tools and high-throughput sequencing technologies to discover novel Mycobacterium tuberculosis antigens and she studies their antigenicity by comprehensive comparison of pathogen-specific immunity in health and disease. Besides, she has been trained as a vaccinologist in the European Network Vactrain.
Melanie J Shears
Participant
[United States] Dr Melanie Shears has recently completed her postdoctoral training in malaria research at Johns Hopkins University. She is moving to begin as a Staff Scientist at the Center for Emerging and Re-emerging Infectious Diseases at the University of Washington. She works on malaria vaccine target identification and vaccine testing in rodents and non-human primates.
Monica A McArthur
Participant
[United States] Dr. McArthur is an Assistant Professor of Pediatrics and a member of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine. Her clinical expertise is Pediatric Infectious Diseases and her research focus is to support the development of vaccines. She performs clinical vaccine trials and is also involved in translational human immunology projects for pathogens such as V cholerae, ETEC, Zika and Dengue Viruses.
Nancy Hiu Lan Leung
Participant
[Hong Kong] Dr Leung is a post-doctoral fellow at the WHO Collaborating Centre for Infectious Disease Epidemiology and Control, the University of Hong Kong, with primary research interest in influenza epidemiology and population immunity. She has experience in the design, implementation and analysis of field studies on influenza burden, transmission, population immunity and vaccine immunogenicity. She aspires to be an immuno-epidemiologist and to study the mechanisms of human immunity.
Olayinka Oluwafemi Asala
Participant
[Nigeria] Dr Olayinka Oluwafemi Asala a principal veterinary research officer at the Nigerian National Veterinary Research Institute (NVRI) Vom. He heads the Viral Vaccines production division. He is a PhD student with interest to characterize and evaluate the efficacy of Newcastle disease vaccine on current circulating virulent Newcastle disease virus in Nigeria at the Institute of Diagnostic Virology, Friedrich-Loeffler Institute, Griefwald Germany.
Oliver Varette
Participant
[Canada] Oliver holds an Honours BSc from McMaster University (Life Science) and is currently a PhD candidate (Microbiology & Immunology, University of Ottawa) in the lab of Dr. Jean-Simon Diallo at the Ottawa Hospital Research Institute (Cancer Therapeutics Program). The central focus of the Diallo laboratory is the study/development of "viral sensitizer" drugs and the potential of these novel compounds to improve the performance of several promising cancer immunotherapy platforms.
Pablo A Romagnoli
Participant
[Argentina] Adjunct Investigator (CONICET) at IUCBC. B.S. and M.S. in Biochemistry (1998) at Universidad Nacional de Córdoba (UNC) and Ph.D. on Immunology and Molecular Pathogenesis (2011) at the Emory Vaccine Research Center, Emory University (Atlanta, GA, USA). Postdoctoral studies on T cell responses to oral infection with L. monocytogenes under Dr. Leo Lefrancois and Kamal Khanna supervision at UCONN Health (Farmington, CT, USA). Leads translational research on IBD at CIMETSA-IUCBC (Córdoba, Argentina).
Rodrigo Ochoa
Participant
[Colombia] Bioengineer, MSc in Basic Biomedical Sciences and PhD(c) in Chemical Sciences. He has experience in the fields of Bioinformatics, Cheminformatics, Modeling and Computational Strategies applied to the design and discovery of drugs and vaccines.
Rosemary Thwaite
Participant
[Spain] PhD student in immunology at the Universitat Autonoma de Barcelona (UAB), Spain, working on the development of recombinant protein nanoparticles as a vaccine strategy against viral diseases in aquaculture. Previously Rosemary worked in gene therapy, on the immunogenicity of adeno-associated viral vectors (AAVs) in the human population. With a background in English language teaching, she also gives classes in scientific writing and communication skills in the Biochemistry Dept. of the UAB.
Sharareh Eskandari
Participant
[Australia] Dr Sharareh Eskandari has been a Postdoctoral Research Fellow at Laboratory of Vaccines for the Developing World (Institute for Glycomics, Australia) since 2016 post completing her PhD at University of Queensland. She has PhD and professional experience in pharmaceutical industry. Currently, her research studies involve developing a preclinical liposome vaccine candidate to protect against group A streptococcus infection. Her interests focus on translational research on vaccine delivery systems.
Vanessa Arato
Participant
[Italy] Vanessa obtained a Master's degree in Cellular and Molecular Biology at the University of Siena in 2014. She was then a post-graduate intern at Novartis Vaccines, where she worked on host-pathogen interaction mechanisms of bacteria such as Bordetella pertussis and Neisseria meningitidis. Vanessa is currently completing her PhD with the University of Padua in a joined program with GSK Vaccines Siena with research focusing on the pathogenesis of Clostridium difficile.
Vijay Kumar Prajapati
Participant
[India] Dr. Vijay Kumar Prajapati is working as Assistant Professor in Department of Biochemistry, Central University of Rajasthan, Ajmer, India. He is working on drug discovery and vaccine development against human infectious diseases. He is a recipient of INSA Medal for Young Scientist and Associate-Indian Academy of Sciences, Bengaluru. He was awarded ASM-IUSSTF Indo-US Research Professorship from The American Society for Microbiology (ASM) and IndoUS Science and Technology Forum (IUSSTF).
Wen-Chun Liu
Participant
[United States] I obtained my Ph.D. degree at biotechnology institute in 2015 from the National Tsing Hua University in Taiwan. From 2016 till now, I am a postdoctoral fellow at the department of Microbiology at Icahn School of Medicine at Mount Sinai in New York. My research interests focus on vaccine development and vaccinology. By using mouse and ferret models, we evaluate the vaccine effectiveness against influenza virus infection and study vaccine-induced immune correlates to the protection.
Yamil Ezequiel Masip
Participant
[Argentina] Yamil graduated in Biotechnology in 2018. His interest in Neglected Tropical Diseases led him to start a PhD in Molecular Biology and Biotechnology, focusing on Chagas disease. His thesis is based on the study of functionality and protective capacity of TcTASV, a newly recently discovered gene family of Trypanosoma cruzi.